Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q1 FY21 results · Apr–Jun 2020
Dr. Lal Path Labs reported revenue from operations of ₹266.00 crore (down 20.6% from Q1 FY20) and net profit of ₹28.40 crore (down 51.9% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 266.00 | 335.20 | −20.6% | 301.70 | −11.8% |
| Other income | 11.40 | 14.40 | −20.8% | 12.00 | −5.0% |
| Total income | 277.40 | 349.60 | −20.7% | 313.70 | −11.6% |
| Profit before tax | 38.10 | 89.40 | −57.4% | 45.40 | −16.1% |
| Net profit for the period | 28.40 | 59.10 | −51.9% | 32.60 | −12.9% |
| EPS, basic (₹) | 3.45 | 7.14 | −51.7% | 3.94 | −12.4% |
| Net margin (%) | 10.7 | 17.6 | 10.8 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 255.00 | 324.50 | −21.4% | 287.50 | −11.3% |
| Other income | 11.10 | 14.10 | −21.3% | 14.00 | −20.7% |
| Total income | 266.10 | 338.60 | −21.4% | 301.50 | −11.7% |
| Profit before tax | 38.50 | 86.70 | −55.6% | 47.60 | −19.1% |
| Net profit for the period | 28.80 | 57.30 | −49.7% | 35.30 | −18.4% |
| EPS, basic (₹) | 3.50 | 6.95 | −49.6% | 4.28 | −18.2% |
| Net margin (%) | 11.3 | 17.7 | 12.3 |
Consolidated
- Filed with BSE
- 31 Jul 2020, 19:31 IST
- Board meeting
- 31 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2020, 19:31 IST
- Board meeting
- 31 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE